Drugs that contain Sumatriptan Succinate

1. Drug name - ALSUMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7811254 MERIDIAN MEDCL Autoinjector with needle depth adapter Aug, 2027

(4 years from now)

Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE;SUBCUTANEOUS Discontinued

2. Drug name - ONZETRA XSAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8047202 CURRAX Nasal devices Jul, 2023

(8 months from now)

US8327844 CURRAX Nasal delivery method Oct, 2023

(11 months from now)

US9119932 CURRAX Nasal delivery device Apr, 2024

(1 year, 6 months from now)

US7975690 CURRAX Nasal devices Aug, 2025

(2 years from now)

US8590530 CURRAX Nasal delivery devices Sep, 2025

(2 years from now)

US9108015 CURRAX Nasal delivery devices Sep, 2025

(2 years from now)

US10124132 CURRAX Nasal delivery Mar, 2027

(4 years from now)

US10398859 CURRAX Nasal delivery devices Dec, 2027

(5 years from now)

US8875704 CURRAX Nasal administration Apr, 2028

(5 years from now)

US10722667 CURRAX Nasal administration Dec, 2028

(6 years from now)

US10076615 CURRAX Nasal delivery Jul, 2029

(6 years from now)

US8550073 CURRAX Nasal delivery Oct, 2029

(7 years from now)

US8899229 CURRAX Powder delivery devices Aug, 2030

(7 years from now)

US9649456 CURRAX Nasal administration Oct, 2030

(8 years from now)

US8978647 CURRAX Nasal delivery Dec, 2030

(8 years from now)

US10478574 CURRAX Nasal administration Nov, 2033

(11 years from now)

US10076614 CURRAX Nasal delivery devices Oct, 2034

(12 years from now)

Treatment: Method of drug delivery via the nasal cavity; Treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; acute treatment of migraine; Treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; method of delivering sumatriptan to a nasal cavity; Acute treatment of migraine; treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; Method of delivering sumatriptan to a nasal cavity

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE POWDER;NASAL Prescription

3. Drug name - SUMAVEL DOSEPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8343130 ENDO VENTURES LTD Needleless injector Oct, 2022

(10 days from now)

US8491524 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof Nov, 2022

(a month from now)

US8241244 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof Nov, 2022

(a month from now)

US8267903 ENDO VENTURES LTD Casing Mar, 2023

(5 months from now)

US8118771 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof Aug, 2023

(10 months from now)

US8241243 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof Aug, 2023

(10 months from now)

US8287489 ENDO VENTURES LTD Device for readying a needle free injector for delivery Dec, 2024

(2 years from now)

US7901385 ENDO VENTURES LTD Casing Jul, 2026

(3 years from now)

US7776007 ENDO VENTURES LTD Device for readying a needle free injector for delivery Nov, 2026

(4 years from now)

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) INJECTABLE;SUBCUTANEOUS Discontinued
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE;SUBCUTANEOUS Discontinued

4. Drug name - ZECUITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6745071 TEVA BRANDED PHARM Iontophoretic drug delivery system Feb, 2023

(4 months from now)

US9427578 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration Apr, 2027

(4 years from now)

US8597272 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration Apr, 2027

(4 years from now)

US8470853 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds Apr, 2027

(4 years from now)

US8155737 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration Apr, 2027

(4 years from now)

US7973058 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds Apr, 2027

(4 years from now)

US9272137 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds Sep, 2027

(4 years from now)

US8366600 TEVA BRANDED PHARM Polyamine enhanced formulations for triptan compound iontophoresis Apr, 2029

(6 years from now)

US8983594 TEVA BRANDED PHARM Electronic control of drug delivery system Nov, 2030

(8 years from now)

US9327114 TEVA BRANDED PHARM User-activated self-contained co-packaged iontophoretic drug delivery system Oct, 2032

(10 years from now)

Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof; Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, using a flowable hydrogel formulation

Dosage: SYSTEM;IONTOPHORESIS

More Information on Dosage
Strength Dosage Availability
EQ 6.5MG BASE/4HR SYSTEM;IONTOPHORESIS Discontinued

5. Drug name - ZEMBRACE SYMTOUCH

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537554 UPSHER SMITH LABS Pharmaceutical composition for treating migraine Jan, 2036

(13 years from now)

Treatment: Treatment of migraine

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.